Irinotecan 100mg Injection

Irinotecan 100mg Injection is a potent antineoplastic agent derived from the natural alkaloid camptothecin. It functions as a specific inhibitor of the enzyme topoisomerase I, a critical nuclear enzyme that relieves torsional strain in DNA during replication and transcription. By stabilizing the complex between topoisomerase I and DNA (“cleavable complex”), Irinotecan 100mg Injection prevents the religation of single-strand DNA breaks. When the replication fork collides with these “roadblocks,” lethal double-strand DNA breaks occur, triggering cell cycle arrest and apoptosis (programmed cell death). This unique mechanism makes it effective against tumors that have developed resistance to other chemotherapy classes like antimetabolites or platinum agents. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for managing advanced gastrointestinal malignancies, offering a powerful option for extending survival in metastatic disease.

The 100mg vial strength is a standard unit for compounding body surface area (BSA)-based doses in oncology pharmacy settings. Irinotecan 100mg Injection is a “prodrug,” meaning it is converted in the body (specifically by the liver enzyme carboxylesterase) into its active metabolite, SN-38, which is approximately 1,000 times more potent than the parent drug. This metabolic activation is key to its intense cytotoxic activity against cancer cells.

Indications / Uses of Irinotecan 100mg Injection

Irinotecan 100mg Injection is commonly prescribed for the specialized management of the following oncological conditions:

• Metastatic Colorectal Cancer (First-Line): It is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin (the FOLFIRI regimen) for patients with metastatic carcinoma of the colon or rectum.
• Metastatic Colorectal Cancer (Second-Line): The medication is used for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
• Pancreatic Cancer (Off-Label): Irinotecan 100mg Injection is a key component of the FOLFIRINOX regimen (along with oxaliplatin, fluorouracil, and leucovorin), which is a standard first-line treatment for metastatic pancreatic adenocarcinoma.
• Small Cell Lung Cancer (SCLC): In certain protocols, it is used in combination with platinum agents (like cisplatin or carboplatin) for the treatment of extensive-stage small cell lung cancer.

Key Features

• Topoisomerase I Inhibition: The primary feature of Irinotecan 100mg Injection is its specific target, offering a mechanism of action that is distinct from alkylating agents or microtubule inhibitors.
• Potent Active Metabolite: Its efficacy is driven by the conversion to SN-38, ensuring high potency at the cellular level.
• Synergistic Combinations: It works exceptionally well in concert with 5-fluorouracil and EGFR inhibitors (like cetuximab), forming the backbone of modern colorectal cancer therapy.
• 150mg/5mL or 100mg/5mL Strength: The 100mg vial size facilitates efficient preparation of standard doses (e.g., 180 mg/m²), reducing waste.
• Intravenous Administration: Administered via IV infusion, typically over 90 minutes, ensuring controlled systemic delivery.

Storage for Irinotecan 100mg Injection

To preserve the chemical stability and ultimate potency of the solution, Irinotecan 100mg Injection should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). It is vital to keep the vial in its original carton to protect it from light until the time of use. Do not freeze the medication, as this can cause precipitation. Once diluted for infusion (usually in D5W or NS), the solution is chemically stable for up to 6 hours at room temperature or 24 hours under refrigeration, but immediate use is recommended to prevent microbiological contamination. Store the medication in a secure, professional medical environment strictly out of the reach of children.

Important Note on Irinotecan 100mg Injection

The administration of Irinotecan 100mg Injection is associated with two distinct types of severe diarrhea. Early Diarrhea (occurring within 24 hours of infusion) is part of a “Cholinergic Syndrome” caused by the drug acting on nerve receptors. Symptoms include sweating, flushing, abdominal cramping, and salivation. This is treated with Atropine.

Late Diarrhea (occurring more than 24 hours after infusion) can be prolonged and life-threatening due to dehydration and electrolyte imbalance. This must be treated immediately and aggressively with Loperamide at the first sign of loose stools. Patients must be educated on this distinction and have loperamide on hand at home.

Severe Myelosuppression (neutropenia) is another critical risk; fatal sepsis has occurred. Blood counts must be monitored before each dose. Patients with a specific genetic variation (homozygous for the UGT1A1*28 allele/Gilbert’s Syndrome) are at increased risk for neutropenia and may require a reduced starting dose. Irinotecan 100mg Injection can cause fetal harm (Pregnancy Category D); effective contraception is mandatory. By strictly following these professional guidelines and managing diarrhea proactively, patients can safely maximize the survival benefits of Irinotecan 100mg Injection.